Summary
This review, published in Nature Reviews Clinical Oncology, examines programmed death-ligand 1 (PD-L1) as a biomarker of response to immune-checkpoint inhibitors in cancer patients. The authors, a multi-institutional consortium, appear to consolidate evidence on PD-L1's utility in predicting ICI efficacy, discussing its role as a companion diagnostic across solid tumour types. The review likely addresses methodological considerations, clinical evidence, and limitations of PD-L1 as a single-agent predictor of immunotherapy response.
UK applicability
This oncology biomarker review is directly applicable to UK clinical practice, as PD-L1 testing informs treatment decisions within the NHS for eligible cancer patients. The findings would support evidence-based stratification of immunotherapy access and tumour board decision-making in UK cancer centres.
Key measures
PD-L1 expression levels (percentage and intensity of staining), response rates to ICIs, progression-free survival, overall survival, biomarker performance across cancer histologies
Outcomes reported
The study examined PD-L1 expression as a biomarker to predict patient response to immune-checkpoint inhibitor (ICI) therapies across multiple cancer types. The work appears to synthesise evidence on PD-L1's prognostic and predictive value in clinical oncology practice.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.